November 9 earnings date set for Celldex Therapeutics stock
Published on 10/15/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and valuation
- Celldex Therapeutics has its next estimated earnings date on November 9, 2026.
- Celldex carried a market capitalization of USD 2.3 billion on October 15, 2026.
- Celldex Therapeutics stock cost EUR 25.46 at Lang & Schwarz on October 15, 2026 at 7:08 p.m. CEST.
- Celldex had a P/E ratio of -6.55 on October 15, 2026.
The next estimated earnings date for Celldex Therapeutics (ISIN US15117B2025) is November 9, 2026, according to MarketBeat. The calendar date gives investors the next scheduled checkpoint for the clinical-stage biotechnology company. Celldex stock was trading at EUR 25.46 at Lang & Schwarz on October 15, 2026 at 7:08 p.m. CEST.
Market value reaches USD 2.3 billion
Celldex had a market capitalization of USD 2.3 billion on October 15, 2026. Its primary listing is Nasdaq under ticker CLDX, and the company operates in the Healthcare sector and Biotechnology industry.
The company is developing antibody-based treatments for inflammatory diseases and cancer. Its lead candidate barzolvolimab targets the KIT receptor on mast cells, while its wider pipeline includes antibody programs intended to modulate immune responses.
Stock remains inside its yearly range
Celldex traded within a 52-week range of USD 22.10 to USD 45.14 on October 15, 2026. The same session recorded volume of 334,858 shares against an average volume of 1,353,360 shares. The primary-market quote stood at USD 28.67 at 1:14 p.m. ET on October 15, 2026.
Negative earnings shape valuation
Celldex carried a P/E ratio of -6.55 on October 15, 2026, reflecting negative trailing earnings. The company does not pay a dividend, so dividend yield does not provide an income comparison for the stock.
Comparison with peers
CLDX (Nasdaq, USD): P/E -6.55, market capitalization USD 2.3 billion
Summit Therapeutics (Nasdaq, USD): plus 1.5 percent, P/E -13.70, market capitalization USD 12.3 billion
AbbVie (NYSE, USD): plus 1.9 percent, P/E 81.06, market capitalization USD 507.5 billion
Next scheduled checkpoint
The next estimated earnings date is November 9, 2026. The date gives the calendar a defined reference point for the next corporate update.
Trading view in euros
Celldex Therapeutics was trading at EUR 25.46 at Lang & Schwarz on October 15, 2026 at 7:08 p.m. CEST. The Nasdaq quote was USD 28.67 at 1:14 p.m. ET on October 15, 2026.
The further course of trading is shown by the continuously updated real-time quote of Celldex Therapeutics stock.
Celldex Therapeutics stock facts
- Company: Celldex Therapeutics, Inc.
- ISIN: US15117B2025
- Ticker: CLDX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 7:08 p.m. CEST): EUR 25.46
- Market capitalization: USD 2.3 billion (as of October 15, 2026)
- 52-week range: USD 22.10-45.14 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 9, 2026
Market context: Market report S&P 500.
